

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

EXHIBIT D

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/106, C07K 14/28, C12N 15/31	A1	(11) International Publication Number: WO 97/29771 (43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number: PCT/IB97/00183 (22) International Filing Date: 17 February 1997 (17.02.97) (30) Priority Data: 9603314.7 16 February 1996 (16.02.96) GB (71) Applicant (for all designated States except US): CHIRON S.P.A. [IT/IT]; Via Fiorentina, 1, I-53100 Siena (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): FONTANA, Maria, Rita [IT/IT]; Istituto Ricerche Immunobiologiche Siena, Via Fiorentina, 1, I-53100 Siena (IT). PIZZA, Mariagrazia [IT/IT]; Istituto Ricerche Immunobiologiche Siena, Via Fiorentina, 1, I-53100 Siena (IT). RAPPUOLI, Rino [IT/IT]; Istituto Ricerche Immunobiologiche Siena, Via Fiorentina, 1, I-53100 Siena (IT). (74) Agent: HALLYBONE, Huw, George; Carpmnaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IMMUNOGENIC DETOXIFIED MUTANTS OF CHOLERA TOXIN (57) Abstract An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof in which at least one amino acid is substituted with another amino acid characterized in that, in purified form, the immunogenic detoxified protein exhibits a residual toxicity greater than 10000 fold lower than its naturally occurring counterpart. In the described embodiment, the amino acid at, or in a position corresponding to Pro-106 is replaced with another amino acid. The immunogenic detoxified protein is useful as vaccine for <i>Vibrio cholerae</i> and is produced by recombinant DNA means by site-directed mutagenesis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

IMMUNOGENIC DETOXIFIED MUTANTS OF CHOLERA TOXIN

Field of the invention

5 The present invention relates to immunogenic detoxified proteins of cholera toxin (CT) wherein at least one amino acid is substituted with another amino acid with the result that, in purified form, the immunogenic detoxified protein exhibits a residual toxicity greater than 10000 fold lower
10 than its naturally occurring counterpart and to their use in vaccines which are useful for the prevention or treatment of cholera and as mucosal adjuvants for other immunogenic proteins. The detoxified immunogenic proteins can be suitably produced using recombinant DNA techniques by site-
15 directed mutagenesis of DNA encoding the wild type toxins.

Background to the Invention

Cholera is a contagious disease widely distributed in the
20 world, in particular in the Third World, where, in certain areas, it is endemic. The serious disorders which develop in the intestinal system prove fatal in a high percentage of the recorded cases of the disease.

25 The etiological agent of cholera is the Gram-negative microorganism *Vibrio cholerae* (*V.cholerae*). This colonises the intestinal tract of individuals who have come into contact with it through ingestion of contaminated food or water, and multiplies to very high concentrations. The
30 principal symptom is severe diarrhoea as a result of which the patient can lose as much as 10-15 litres of liquids per day via the faeces. As a result of the severe dehydration and loss of electrolytes, the patient does not withstand the infection in 50-60% of cases, and dies. The diarrhoea caused
35 by *V.cholerae* is due to the secretion of cholera toxin, CT, which acts by stimulating the activity of the adenylate cyclase enzyme so as to induce disturbances at cell level.

Although cholera can be effectively cured by controlled and intense rehydration, the distribution of a vaccine is desirable with a view to complete control and future eradication of the disease.

5

At the present time, there exists a vaccination against cholera, consisting of parenteral administration of killed bacteria. Although some countries insist on vaccination against the disease, there are serious doubts as to its real
10 usefulness, given that the current cellular vaccine protects against the consequences of the infection in only 50% of the cases and that the protection is also extremely limited in duration, to less than 6 months.

15 In Bangladesh, an experimental trial is in progress (1990-92) of an oral vaccine consisting of killed bacteria with the addition of subunit B of cholera toxin, which is known to be highly immunogenic. This product succeeds in inducing lasting protection, without special side effects (Holmgren
20 J., Clemens J., Sack DA., Sanchez J. and Svennerholm AM; "Oral Immunization against cholera" Curr. Top. Microbiol. Immunol. (1988), 146, 197-204).

The CT toxin comprises a single A subunit (or protomer A)
25 responsible for the enzymic activity of the toxin (herein CT-A) and five identical B subunits (or protomer B) which are involved in the binding of the toxin to the intestinal epithelial cells (herein CT-B).

30 The A subunit penetrates the cell membrane and causes activation of adenylate cyclase by NAD-dependent ADP-ribosylation of a GTP-binding protein which controls the activity of the enzyme. The clinical effect of this is to cause massive fluid loss into the intestine.

35

Considerable research has been conducted on cholera toxin. Its sequence is known and has been described (Mekalanos J.J. et al Nature 306, page 551 (1983)).

In view of the potential clinical significance of vaccines against cholera there is a continuing and great interest in producing a detoxified toxin capable of immunising against cholera. The techniques of genetic engineering allow
5 specific mutations to be introduced into the genes encoding the toxins and the production of the mutated toxins using now conventional techniques of gene expression and protein purification.

- 10 Kaslow, H.R. et al (Abstract B291 of the 92nd General Meeting of the American Society for Microbiology, 26-30th May 1992) describe mutating Asp-9 and His-44 and truncating after amino acid 180 in CT-A which all essentially eliminate activity. Mutating Arg-9 is said to markedly attenuate
15 activity. Mutating other amino acid sites had little effect on toxicity.

- Burnette, W.N. et al (Inf. and Immun. 59(11), 4266-4270, (1991)) describe site-specific mutagenesis of CT-A to
20 produce an Arg-7-Lys mutation paralleling that of a known detoxifying mutation in the A subunit of the *Bordetella pertussis* toxin. The mutation resulted in the complete abolition of detectable ADP-ribosyltransferase activity.

- 25 International patent application WO 92/19265 (Burnette, Kaslow and Amgen Inc.) describes mutations of CT-A at Arg-7, Asp-9, Arg-11, His-44, His-70 and Glu-112.

- A mutations at Glu-110 has also been described in the
30 literature (Lobet, Inf. Immun., 2870, 1991; Lai, Biochem. Biophys. Res. Comm. 341 1983; Okamoto J. Bacteriol. 2208, 1988).

- It is known that the development of toxicity of the A
35 subunits of CT requires proteolytic cleavage of A1 and A2 subunits at around amino acid Arg-192 (Grant et al Inf. & Immun. (1994) 62(10) 4270-4278).

Immunogenic detoxified proteins comprising the amino acid sequence of subunit A of a cholera toxin or a fragment thereof, wherein one or more amino acids at, or in positions corresponding to Val-53, Ser-63, Val-97, Tyr-104 or Pro-106 are replaced with another amino acid are disclosed in WO 93/13202 (Biocine Sclavo SpA). Optionally the amino acid sequence may include other mutations such as, for example, substitutions at one or more of Arg-7, Asp-9, Arg-11, His-44, Arg-54, Ser-61, His-70, His-107, Glu-110, Glu-112, Ser-114, Trp-127, Arg-146 or Arg-192. These mutations are described as being completely detoxified as measured by the assays described.

A double mutant comprising the amino acid sequence of CT-A or a fragment thereof is described in UK patent application 9513371.6 (filed 30th June 1995) wherein the amino acids at, or in positions corresponding to, Ser-63 and Arg-192 are replaced with another amino acid.

Detoxified mutants of pertussis toxin have been reported to be useful both for direct intranasal vaccination and as a mucosal adjuvant for other vaccines (Roberts et al Inf. & Immun. (1995) 63(6) 2100-2108). Published International patent application WO 95/17211 (Biocine SpA) describes the use of detoxified mutants of CT as mucosal adjuvants.

Summary of the invention

We have discovered that a residual low level of toxicity provides an improved altered CT for use in a vaccine and/or a mucosal adjuvant.

Although detoxified in the sense of having a much lower toxicity than the wild-type protein, these proteins retain traces of enzymatic activity. The mutation causes a decrease of in vivo toxicity of at least 10000 fold and this makes the protein very useful for human use. In addition to the immunological and adjuvant properties typical of mutants

devoid of enzymatic activity, the mutant protein surprisingly exhibits an increase in adjuvant activity.

According to the present invention, there is provided an
5 immunogenic detoxified protein comprising the amino acid
sequence of subunit A of a cholera toxin (CT-A) or a
fragment thereof wherein at least one amino acid is
substituted with another amino acid characterised in that,
in purified form, the immunogenic detoxified protein
10 exhibits a residual toxicity greater than 10000 fold lower
than its naturally occurring counterpart.

The immunogenic detoxified protein according to the present
invention exhibits a carefully selected balance of toxicity
15 maximising the immunogenicity and/or adjuvant effects of the
protein whilst maintaining a sufficiently low toxicity to be
tolerated by the immunised individual.

Preferably the amino acid at, or in a position corresponding
20 to, Pro-106 is replaced with another amino acid.

That this particular preferred embodiment would exhibit the
claimed features was not predictable from the prior art
which generally teaches that absolute removal of toxicity
25 was the goal for the development of mutant toxin vaccines
and adjuvants and in particular teaches that this particular
mutated toxin would have no toxicity (see WO 93/13202).

In this specification, references to CT encompass the
30 various naturally occurring strain variants as well other
variants encompassing changes from the sequences disclosed
herein which do not affect the immunogenicity of the
assembled toxoid.

35 The amino acid sequences for CT are definitively described
in Domenighini et al Molecular Microbiology (1995) 15(6)
1165-1167.

The amino acid substituted for the wild type amino acid may be a naturally occurring amino acid or may be a modified or synthetic amino acid, provided that the mutant retains the necessary immunogenic properties and exhibits a greater than
5 10 000 fold reduction in toxicity relative to the naturally occurring counterpart. The substitution may involve deletion or addition of one or more amino acids.

Substitutions which alter the amphotericity and
10 hydrophilicity whilst retaining the steric effect of the substituting amino acid as far as possible are generally preferred.

As used herein, the term "detoxified" means that the
15 immunogenic composition exhibits greater than 10 000 fold reduction in toxicity relative to its naturally occurring toxin counterpart. The reduction in toxicity should be sufficiently low for the protein to be used in an immunogenic composition in an immunologically effective
20 amount as a vaccine with causing significant side effects.

As used herein, the term "residual toxicity" means that the detoxified immunogenic protein retains a measurable toxicity. More particularly the level of toxicity is
25 optimised by balancing increased immunogenicity/adjuvantcity against the toxic effects of administration in a benefit/side effect trade-off.

The residual toxicity of the immunogenic composition is
30 greater than 10 000 fold reduced relative to its natural occurring counterpart, preferably greater than 30 000 fold and most preferably greater than 50 000 fold.

The toxicity may be measured in mouse CHO cells or
35 preferably by the rabbit ileal loop assay or by evaluation of the morphological changes induced in Y1 cells.

Most preferably the toxicity of the immunogenic composition

is reduced relative to its natural occurring counterpart by about 30 000 fold as measured by the evaluation of the morphological changes induced in Y1 cells or 10 000 fold as measured by the rabbit ileal loop assay.

5

The term "toxoid" as used herein means a genetically detoxified toxin.

10 The immunogenic protein may be a CT subunit A toxoid, but is preferably an assembled toxin molecule comprising a mutated CT-A subunit and five B subunits of CT. The B subunit may be a naturally occurring subunit or may itself be mutated.

15 The immunogenic protein is preferably a naturally occurring CT-A suitably modified as described above. However, conservative amino acid changes may be made which do not affect the immunogenicity or the toxicity of immunogenic protein and preferably do not affect the ability of the immunogenic protein to form complete toxin with B subunit
20 protein. Also, the immunogenic protein may be a fragment of CT-A provided that the fragment is immunogenic and non toxic and contains at least one of the conserved regions containing one of the mutations according to the invention.

25 Preferably Pro-106 is replaced with Ser-106.

According to a second aspect of the invention, there is provided an immunogenic composition for use as a vaccine comprising an immunogenic detoxified protein of the first
30 aspect of the invention and a pharmaceutically acceptable carrier.

The invention also provides a vaccine composition comprising an immunogenic detoxified protein according to the first
35 aspect of the invention and a pharmaceutically acceptable carrier. The vaccine composition may further comprise an adjuvant. Alternatively, the vaccine composition may comprise a second antigen capable of raising an

immunological response to another disease. In such an alternative composition, the immunogenic detoxified protein acts as a mucosal adjuvant.

- 5 According to a third aspect of the invention, there is provided a method of vaccinating a mammal against *Vibrio cholerae* comprising administering an immunologically effective amount of an immunogenic detoxified protein according to the first aspect of the invention. Optionally,
- 10 the immunogenic detoxified protein of the invention may act as an adjuvant for a second immunogenic protein administered separately, sequentially or with the immunogenic detoxified protein of the invention.
- 15 The immunogenic detoxified proteins of the invention may be synthesised chemically using conventional peptide synthesis techniques, but are preferably produced by recombinant DNA means.
- 20 According to a fourth aspect of the invention there is provided a DNA sequence encoding an immunogenic detoxified protein according to the first aspect of the invention.

Preferably the DNA sequence contains a DNA sequence encoding

25 a complete CT comprising DNA encoding both the detoxified subunit A and subunit B in a polycistronic unit. Alternatively, the DNA may encode only the detoxified subunit A.

- 30 According to a fifth aspect of the invention, there is provided a vector carrying a DNA according to the fourth aspect of the invention.

According to a sixth aspect of the invention, there is

35 provided a host cell line transformed with the vector according to the fifth aspect of the invention.

The host cell may be any host capable of producing CT or but

is preferably a bacterium, most suitably *E.coli* or *V.cholerae* suitably engineered to produce the desired immunogenic detoxified protein.

5 In a further embodiment of the sixth aspect of the invention, the host cell may itself provide a protective species, for example a *V.cholerae* strain mutated to a phenotype lacking wild type CT and carrying and expressing an immunogenic detoxified protein of the first aspect of the
10 invention.

In a further embodiment of the sixth aspect of the invention the host cell is capable of expressing a chromosomal CT-A gene according to the first aspect of the invention.

15

According to a seventh aspect of the invention, there is provided a process for the production of an immunogenic detoxified protein according to the first aspect of the invention comprising culturing a host cell according to the
20 sixth aspect of the invention.

According to a eighth aspect of the invention there is provided a process for the production of DNA according to the fourth aspect of the invention comprising the steps of
25 subjecting a DNA encoding a CT-A or a fragment thereof to site-directed mutagenesis.

According to a ninth aspect of the invention there is provided a process for the formulation of a vaccine
30 comprising bringing an immunogenic detoxified protein according to the first aspect of the invention into association with a pharmaceutically acceptable carrier and optionally with an adjuvant.

35 Industrial Applicability

The immunogenic detoxified protein of the invention constitutes the active component of a vaccine composition

useful for the prevention and treatment of cholera infections. The immunogenic detoxified protein may also be used in a vaccine composition as a mucosal adjuvant. The compositions are thus applicable for use in the pharmaceutical industry.

Detailed Description of Embodiments of the Invention

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, et al., MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D.N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed, 1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, VOLUMES I-IV (D.M. Weir and C. C. Blackwell eds 1986).

Standard abbreviations for nucleotides and amino acids are used in this specification. All publications, patents, and patent applications cited herein are incorporated by reference.

In particular, the following amino acid abbreviations are used:

	Alanine	A	Ala	Arginine	R	Arg
5	Asparagine	N	Asn	Aspartic Acid	D	Asp
	Cysteine	C	Cys	Glycine	G	Gly
	Glutamic Acid	E	Glu	Glutamine	Q	Gln
	Histidine	H	His	Isoleucine	I	Ile
	Leucine	L	Leu	Lysine	K	Lys
10	Methionine	M	Met	Phenylalanine	F	Phe
	Proline	P	Pro	Serine	S	Ser
	Threonine	T	Thr	Tryptophan	W	Trp
	Tyrosine	Y	Tyr	Valine	V	Val

15 As mentioned above examples of the immunogenic detoxified protein that can be used in the present invention include polypeptides with minor amino acid variations from the natural amino acid sequence of the protein other than at the sites of mutation specifically mentioned.

20

A significant advantage of producing the immunogenic detoxified protein by recombinant DNA techniques rather than by isolating and purifying a protein from natural sources is that equivalent quantities of the protein can be produced by
 25 using less starting material than would be required for isolating the protein from a natural source. Producing the protein by recombinant techniques also permits the protein to be isolated in the absence of some molecules normally present in cells. Indeed, protein compositions entirely
 30 free of any trace of human protein contaminants can readily be produced because the only human protein produced by the recombinant non-human host is the recombinant protein at issue. Potential viral agents from natural sources and viral components pathogenic to humans are also avoided.
 35 Also, genetically detoxified toxin are less likely to revert to a toxic form than more traditional, chemically detoxified toxins.

Pharmaceutically acceptable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized
5 macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes) and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
10 Additionally, these carriers may function as immunostimulating agents (adjuvants).

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: aluminum salts
15 (alum) such as aluminium hydroxide, aluminium phosphate, aluminium sulfate etc., oil emulsion formulations, with or without other specific immunostimulating agents such as muramyl peptides or bacterial cell wall components, such as for example (1) MF59 (Published International patent
20 application WO-A-90/14837, containing 5% Squalene, 0.5% Tween® 80, 0.5% Span® 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA
25 02164), (2) SAF, containing 10% squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (3) RIBI™ adjuvant system (RAS) (Ribi Immunochem, Hamilton, MT)
30 containing 2% Squalene, 0.2% Tween® 80 and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS) preferably MPL+CWS (Detox™), muramyl peptides such as N-acetyl-muramyl-L-threonyl-D-
35 isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminy-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE) etc., and

cytokines, such as interleukins (IL-1, IL-2 etc) macrophage colony stimulating factor (M-CSF), tumour necrosis factor (TNF) etc. Additionally, saponin adjuvants, such as Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used
5 or particles generated therefrom such as ISCOMS (immunostimulating complexes). Furthermore, Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA) may be used. Alum and MF59 are preferred.

10 The immunogenic detoxified protein of the invention may used as an adjuvant for a second antigen in an immunologically active composition for the treatment or vaccination of the human or animal body.

15 The immunogenic compositions (e.g. the antigen, pharmaceutically acceptable carrier and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and
20 the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in,
25 liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect as discussed above under pharmaceutically acceptable carriers.

30 Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount
35 to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic

- group of individual to be treated (e.g., nonhuman primate, primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.
- 10 The immunogenic compositions are conventionally administered parenterally, e.g. by injection either subcutaneously or intramuscularly. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories and transdermal applications.
- 15 Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.

The term "polynucleotide" as used herein refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications, for example, labels which are known in the art, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages (e.g.,

phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example proteins (including for e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide.

10

A "replicon" is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control. This may include selectable markers.

15

A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.

20

"Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

25

30

"Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated

35

in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

- 5 An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence.
- 10 A "coding sequence" is a polynucleotide sequence which is translated into a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation
- 15 stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, cDNA, and recombinant polynucleotide sequences.

"PCR" refers to the technique of polymerase chain reaction

20 as described in Saiki, et al., Nature 324:163 (1986); and Scharf et al., Science (1986) 233:1076-1078; and U.S. 4,683,195; and U.S. 4,683,202.

As used herein, x is "heterologous" with respect to y if x

25 is not naturally associated with y in the identical manner; i.e., x is not associated with y in nature or x is not associated with y in the same manner as is found in nature.

"Homology" refers to the degree of similarity between x and

30 y. The correspondence between the sequence from one form to another can be determined by techniques known in the art. For example, they can be determined by a direct comparison of the sequence information of the polynucleotide. Alternatively, homology can be determined by hybridization

35 of the polynucleotides under conditions which form stable duplexes between homologous regions (for example, those which would be used prior to S_1 digestion), followed by digestion with single-stranded specific nuclease(s), fol-

lowed by size determination of the digested fragments.

As used herein, the term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.

The protein may be used for producing antibodies, either monoclonal or polyclonal, specific to the protein. The methods for producing these antibodies are known in the art.

"Recombinant host cells", "host cells," "cells," "cell cultures," and other such terms denote, for example, microorganisms, insect cells, and mammalian cells, that can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not

necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation. Examples for mammalian host cells include Chinese hamster ovary (CHO) and monkey kidney (COS) cells.

Specifically, as used herein, "cell line," refers to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants. The term "cell lines" also includes immortalized cells. Preferably, cell lines include nonhybrid cell lines or hybridomas to only two cell types.

As used herein, the term "microorganism" includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and filamentous fungi.

"Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.

By "genomic" is meant a collection or library of DNA molecules which are derived from restriction fragments that have been cloned in vectors. This may include all or part of the genetic material of an organism.

By "cDNA" is meant a complementary DNA sequence that

hybridizes to a complementary strand of DNA.

By "purified" and "isolated" is meant, when referring to a polypeptide or nucleotide sequence, that the indicated
5 molecule is present in the substantial absence of other biological macromolecules of the same type. The term "purified" as used herein preferably means at least 75% by weight, more preferably at least 85% by weight, more preferably still at least 95% by weight, and most preferably
10 at least 98% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000, can be present).

15 Once the appropriate coding sequence is isolated, it can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, bacteria, and yeast.

20 i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3')
25 transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation
30 site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at
35 which transcription is initiated and can act in either orientation [Sambrook et al. (1989) "Expression of Cloned Genes in Mammalian Cells." In Molecular Cloning: A Laboratory Manual, 2nd ed.].

Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter [Maniatis et al. (1987) Science 236:1237; Alberts et al. (1989) Molecular Biology of the Cell, 2nd ed.]. Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer [Dijkema et al (1985) EMBO J. 4:761] and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus [Gorman et al. (1982b) Proc. Natl. Acad. Sci. 79:6777] and from human cytomegalovirus [Boshart et al. (1985) Cell 41:521]. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion [Sassone-Corsi and Borelli (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237].

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the

DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by
5 in vitro incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader
10 sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal
15 peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

20 Usually, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding
25 sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation [Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In Transcription and splicing (ed. B.D.
30 Hames and D.M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105]. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived
35 from SV40 [Sambrook et al (1989) "Expression of cloned genes in cultured mammalian cells." In Molecular Cloning: A Laboratory Manual].

Some genes may be expressed more efficiently when introns (also called intervening sequences) are present. Several cDNAs, however, have been efficiently expressed from vectors that lack splicing signals (also called splice donor and acceptor sites) [see e.g., Gething and Sambrook (1981) Nature 293:620]. Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the primary transcript [Nevins (1983) Annu. Rev. Biochem. 52:441; Green (1986) Annu. Rev. Genet. 20:671; Padgett et al. (1986) Annu. Rev. Biochem. 55:1119; Krainer and Maniatis (1988) "RNA splicing." In Transcription and splicing (ed. B.D. Hames and D.M. Glover)].

15

Usually, the above described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40 [Gluzman (1981) Cell 23:175] or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a procaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2 [Kaufman et al. (1989) Mol. Cell. Biol. 9:946 and pHEBO [Shimizu et al. (1986) Mol.

35

Cell. Biol. 6:1074].

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

ii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art.

Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome, and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

After inserting the DNA sequence encoding the protein into

the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant
5 plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully
10 described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein
15 into the baculovirus genome, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a
20 single gene and operably linked regulatory elements; multiple genes, each with its own set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a
25 replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

30

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also been designed. These include, for example, pVL985 (which alters
35 the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.

The plasmid usually also contains the polyhedrin polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a procaryotic ampicillin-resistance (amp) gene and origin of replication for selection and
5 propagation in E. coli.

Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and
10 initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually
15 includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

20

Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al.,
25 (1986) "The Regulation of Baculovirus Gene Expression," in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and the gene encoding the p10 protein, Vlak et al., (1988), J. Gen. Virol. 69:765.

30

DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell et al. (1988) Gene, 73:409). Alternatively, since the signals for
35 mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear

accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human α -interferon, Maeda et al., (1985), Nature 315:592; 5 human gastrin-releasing peptide, Lebacqz-Verheyden et al., (1988), Molec. Cell. Biol. 8:3129; human IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404; mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human glucocerebrosidase, Martin et al. (1988) DNA, 7:99, can also 10 be used to provide for secretion in insects.

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good 15 intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from 20 the mature protein by in vitro incubation with cyanogen bromide.

Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect 25 cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct 30 the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect 35 cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will

usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith supra; Ju et al. (1987); Smith et al.,
5 Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene.
10 Miller et al., (1989), Bioessays 4:91. The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.
15
The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the
20 majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which
25 is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15 μ m in size, are highly
30 refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of
35 insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion

bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith, supra; Miller et al. (1989).

5 Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for, inter alia: Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and
10 Trichoplusia ni (PCT Pub. No. WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225).

15

Cells and cell culture media are commercially available for both direct and fusion expression of heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in
20 the art. See, e.g., Summers and Smith supra.

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable maintenance of the plasmid(s) present in the modified insect
25 host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed into the medium and the nutrient medium must be continuously
30 circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; electrophoresis; density gradient centrifugation; solvent
35 extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a

product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

iii. Bacterial Systems

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *Escherichia coli* (*E. coli*) [Raibaud et al. (1984) Annu. Rev. Genet. 18:173]. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing

transcription.

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include
5 promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) [Chang et al. (1977) Nature 198:1056], and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp) [Goeddel et al. (1980) Nuc. Acids Res.
10 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. Patent No. 4,738,921; EPO Publ. Nos. 036 776 and 121 775]. The g-laotamase (bla) promoter system [Weissmann (1981) "The cloning of interferon and other mistakes." In Interferon 3 (ed. I. Gresser)], bacteriophage lambda PL [Shimatake et al.
15 (1981) Nature 292:128] and T5 [U.S. Patent No. 4,689,406] promoter systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example,
20 transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter [U.S. Patent No. 4,551,433]. For example, the tac promoter is a hybrid
25 trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor [Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21]. Furthermore, a bacterial promoter can include naturally occurring promoters of non-
30 bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The
35 bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system [Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074]. In addition, a hybrid promoter can also be

comprised of a bacteriophage promoter and an E. coli operator region (EPO Publ. No. 267 851).

In addition to a functioning promoter sequence, an efficient
5 ribosome binding site is also useful for the expression of
foreign genes in prokaryotes. In E. coli, the ribosome
binding site is called the Shine-Dalgarno (SD) sequence and
includes an initiation codon (ATG) and a sequence 3-9
nucleotides in length located 3-11 nucleotides upstream of
10 the initiation codon [Shine et al. (1975) Nature 254:34].
The SD sequence is thought to promote binding of mRNA to the
ribosome by the pairing of bases between the SD sequence and
the 3' end of E. coli 16S rRNA [Steitz et al. (1979)
"Genetic signals and nucleotide sequences in messenger RNA."
15 In Biological Regulation and Development: Gene Expression
(ed. R.F. Goldberger)]. To express eukaryotic genes and
prokaryotic genes with weak ribosome-binding site [Sambrook
et al. (1989) "Expression of cloned genes in *Escherichia*
coli." In Molecular Cloning: A Laboratory Manual].

20

A DNA molecule may be expressed intracellularly. A promoter
sequence may be directly linked with the DNA molecule, in
which case the first amino acid at the N-terminus will
always be a methionine, which is encoded by the ATG start
25 codon. If desired, methionine at the N-terminus may be
cleaved from the protein by in vitro incubation with
cyanogen bromide or by either in vivo or in vitro incubation
with a bacterial methionine N-terminal peptidase (EPO Publ.
No. 219 237).

30

Fusion proteins provide an alternative to direct expression.
Usually, a DNA sequence encoding the N-terminal portion of
an endogenous bacterial protein, or other stable protein, is
fused to the 5' end of heterologous coding sequences. Upon
35 expression, this construct will provide a fusion of the two
amino acid sequences. For example, the bacteriophage lambda
cell gene can be linked at the 5' terminus of a foreign gene
and expressed in bacteria. The resulting fusion protein

preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene [Nagai et al. (1984) Nature 309:810]. Fusion proteins can also be made with sequences from the lacZ [Jia et al. (1987) Gene 60:197], trpE [Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11], and Chey [EPO Publ. No. 324 647] genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated [Miller et al. (1989) Bio/Technology 7:698].

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria [U.S. Patent No. 4,336,336]. The signal sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA) [Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:2437] and the E. coli alkaline phosphatase signal sequence (phoA) [Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212]. As an additional example, the signal

sequence of the alpha-amylase gene from various *Bacillus* strains can be used to secrete heterologous proteins from *B. subtilis* [Palva *et al.* (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. No. 244 042].

5

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the
10 transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include
15 transcription termination sequences derived from genes with strong promoters, such as the *trp* gene in *E. coli* as well as other biosynthetic genes.

Usually, the above described components, comprising a
20 promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable
25 maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to be maintained in a procaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid
30 will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector
35 may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated

into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from
5 recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage
10 or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed.
15 Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline [Davies et al. (1978) Annu. Rev. Microbiol. 32:469]. Selectable markers may also
20 include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above described components can be put together in transformation vectors. Transformation
25 vectors are usually comprised of a selectable market that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either extra-
30 chromosomal replicons or integrating vectors, have been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: *Bacillus subtilis* [Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541],
35 *Escherichia coli* [Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829 and 136

907], *Streptococcus cremoris* [Powell et al. (1988) Appl. Environ. Microbiol. 54:655]; *Streptococcus lividans* [Powell et al. (1988) Appl. Environ. Microbiol. 54:655], *Streptomyces lividans* [U.S. Patent No. 4,745,056].

5

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with CaCl_2 or other agents, such as divalent cations and DMSO. DNA can also be
10 introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See e.g., [Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063
15 953; PCT Publ. No. WO 84/04541, *Bacillus*], [Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, *Campylobacter*], [Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner (1978) "An improved method for
20 transformation of *Escherichia coli* with ColE1-derived plasmids. In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318;
25 *Escherichia*], [Chassy et al. (1987) FEMS Microbiol. Lett. 44:173 *Lactobacillus*]; [Fiedler et al. (1988) Anal. Biochem 170:38, *Pseudomonas*]; [Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, *Staphylococcus*], [Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987)
30 "Transformation of *Streptococcus lactis* by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infec. Immun. 32:1295; Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Eur. Cong. Biotechnology 1:412,
35 *Streptococcus*].

iv. Yeast Expression

Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences [Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1].

30

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197 and 4,880,734). Other examples of hybrid

promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, OR PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publ. No. 164 5 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, [Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 10 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resistance Genes i the Yeast *Saccharomyces cerevisiae*," in: Plasmids of Medical, Environmental and 15 Commercial Importance (eds. K>N> Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109;].

A DNA molecule may be expressed intracellularly in yeast. 20 A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from 25 the protein by in vitro incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N- 30 terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, 35 can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056. Another example is

a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein.

5 Through this method, therefore, native foreign protein can be isolated (see, e.g., PCT Publ. No. WO 88/024066).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA
10 molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader
15 sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from
20 genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 62,096,086) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for
25 secretion in yeast (EPO Publ. No. 060 057).

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types
30 of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (usually about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,083 and 4,870,008; EPO Publ. No. 324 274). Additional
35 leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alphafactor. (See e.g., PCT Publ. No.

WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation
5 stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences,
10 such as those coding for glycolytic enzymes.

Usually, the above described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together
15 into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for
20 example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24 [Botstein *et al.* (1979) Gene 8:17-24], pCl/1 [Brake *et al.* (1984) Proc. Natl. Acad. Sci USA 81:4642-4646], and YRp17 [Stinchcomb *et al.*
25 (1982) J. Mol. Biol. 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will
30 preferably have at least about 10, and more preferably at least about 20. Enter a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See e.g., Brake *et al.*, *supra*.

35 Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to

integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver *et al.* (1983) Methods in Enzymol. 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver *et al.*, *supra*. One or more expression construct may integrate, possibly affecting levels of recombinant protein produced [Rine *et al.* (1983) Proc. Natl. Acad. Sci. USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions [Butt *et al.* (1987) Microbiol. Rev. 51:351].

Alternatively, some of the above described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector, as described above.

Expression and transformation vectors, either

extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: *Candida albicans* [Kurtz, et al. (1986) Mol. Cell. Biol. 6:142], *Candida maltose* [Kunze, et al. (1985) J. Basic Microbiol. 25:141]. *Hansenula polymorpha* [Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302], *Kluyveromyces fragilis* [Das, et al. (1984) J. Bacteriol. 158:1165], *Kluyveromyces lactis* [De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990) Bio/Technology 8:135], *Pichia guillermondii* [Kunze et al. (1985) J. Basic Microbiol. 25:141], *Pichia pastoris* [Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. Patent Nos. 4,837,148 and 4,929,555], *Saccharomyces cerevisiae* [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163], *Schizosaccharomyces pombe* [Beach and Nurse (1981) Nature 300:706], and *Yarrowia lipolytica* [Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al. (1985) Curr. Genet. 10:49].

Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See e.g., [Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141; *Candida*]; [Gleeson et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; *Hansenula*]; [Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135; *Kluyveromyces*]; [Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. Patent Nos. 4,837,148 and 4,929,555; *Pichia*]; [Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163 *Saccharomyces*]; [Beach and Nurse (1981) Nature 300:706;

[Schizosaccharomyces]; [Davidow *et al.* (1985) *Curr. Genet.* 10:39; Gaillardin *et al.* (1985) *Curr. Genet.* 10:49; Yarrowia].

5 1 Preparation of CT-S106 mutant

1.1 Source of CT DNA

A 1.1 kb *XbaI-HindIII* fragment of pJM17 plasmid (Pearson *et al.* (1982) *PNAS USA* 79: 2976-2980), containing the *ctxAB* gene, was amplified by the polymerase chain reaction (PCR) using the following oligonucleotide primers:

'GGCAGATTCTAGACCTCCTGATGAAATAAA' (*ctxA*)

and

15 'TGAAGTTTGGCGAAGCTTCTTAATTTGCCATACTAATTGCG' (*ctxB*).

(The 5' *XbaI* site corresponds to the site in pJM17 and the 3' *HindIII* site was created by the PCR procedure). The amplified *XbaI-HindIII* fragment was subcloned in pEMBL 19 vector (Dente *et al.* (1983) *NAR* 11: 1645-1655), generating the pEMBL19-CT vector which was used for site-directed mutagenesis (Zoller *et al.* (1982) *NAR* 10:6487).

1.2 Methods of mutation

25

Site-directed mutagenesis was performed according to the method of Zoller (see above) on single-stranded DNA of pEMBL19-CT plasmid. The oligonucleotide used:

'GGCATACAGTAGCCATCCAGA' (oligoCT-S106)

30 mutates the codon for Pro106 to a Ser codon.

1.3 Expression and purification of the CT-S106 mutant.

The mutated *XbaI-HindIII* fragment containing the S106 mutation (Pro106-Ser) was subcloned under the control of CT promoter into pGEM-3 vector (Promega, Madison, USA), generating the pGEM/CT-S106 vector. *V. cholerae* 0395-NT strains were transformed with pGEM/CT-S106 plasmid by

electroporation (Sambrook et al. (1989) Molecular cloning -
A laboratory manual. Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY). The mutant protein was purified
from the culture supernatant of *V. cholerae* strain and
5 purified.

After culturing transformed *V. cholerae* in Syncase modified
medium (Lebens et al. (1993) Biotechnology 11:1574-1578),
the culture was centrifuged and the secreted soluble CT-S106
10 protein was precipitated from the culture supernatant by
adding 2.5 g/l sodium hexametaphosphate and then adjusting
to pH 4.5 with concentrated HCl (Rappaport et al. (1974)
Infect. Immun. 9:294). After centrifuging, the resulting
precipitate was re-dissolved in 0.1 M sodium phosphate, pH
15 8, dialyzed against 10 mM sodium phosphate, pH 7 (Mekalanos
et al. (1988) Methods Enzymol. 165:169-175), and loaded on
a CM-Sepharose column (Pharmacia LKB, Uppsala, Sweden). The
column was eluted first with 20 mM sodium phosphate buffer,
pH 7.5, and then with 40 mM sodium phosphate buffer, pH 7.5.

20

2 Properties of the CT-S106 mutant

2.1 Toxicity

25 Toxic activity on Y1 cells.

The morphological change caused by CT on Y1 adrenal cells
(Donta et al. (1973) Science 183:334) was used to detect the
toxic activity of the CT-S106 mutant. 25µl of medium
(nutrient mixture Ham's F-10 supplemented with 2mM
30 glutamine, 50mg gentamycin, 1.5% horse serum) was added to
each well of the microtitre plate. 25µl of protein solution,
containing 80pg of wild-type CT or 18.75µg of CT-S106, was
added in the first well and then twelve serial 1:2 dilutions
were made (till 1:4096). 50,000 cells were added to each
35 well (200µl volume) and then the plate was incubated at 37°C
in a humidified atmosphere of 95% air, 5% CO₂. The results
were recorded after 48hr of incubation by visual inspection
of the wells using an inverted microscope.

Wild-type CT was toxic until the 1:4 dilution and was non-toxic from the 1:8 dilution; CT-S106 was toxic until 1:32 dilution, and was non-toxic from 1:64 dilution.

- 5 CT is therefore toxic at concentrations of 10pg/well and greater, and non-toxic at concentrations of 5pg/well and below; CT-S106 is toxic at concentrations of 0.6µg/well and greater, and non-toxic at 0.3µg/well and below. This represents a 30,000x reduction in toxicity.

10

Rabbit ileal loop assay.

- New Zealand adult rabbits (ca. 2.5 kg) were used for the assay. The rabbits were starved for 24 hrs before the experiment. Before the operation, the rabbits were
15 anaesthetised and fixed on the operation table. The abdomen of the rabbit was opened with a scalpel and the intestine was extracted. The caecum was located, and 20-30 cm away from this tract of intestine (towards the stomach) 12-14 loops were made (each 5-6 cm in length) up to the
20 approximate end of the intestine proximal to the stomach.

- Five 1ml samples of wild-type CT in PBS buffer were prepared with concentrations of 1.00, 0.50, 0.25, 0.10, 0.05 µg/ml. Mutant CT-S106 was similarly diluted to give five 1ml
25 samples with concentrations of 750, 100, 10, 1, 0.5 µg/ml. The samples was injected into separate ileal loops, with a control loop receiving 1ml PBS. The abdomen was then closed.

- After 18-20 hrs, the volume of liquid accumulated in each
30 loop was measured with a syringe. The length of each loop was measured again. The results, from 4 different rabbits, expressed as volume of liquid per unit length of the loop (ml/cm) are reported in the Tables 1 and 2.

- 35 These data show that as little as 50ng of wild-type CT was able to induce a fluid accumulation in the intestinal loop of rabbits, whereas 100µg of CT-S106 did not produce

significant fluid accumulation, this requiring 750 μ g of CT-S106.

TABLE 1: TOXICITY CURVE OF WILD-TYPE CT

5

μ g of toxin	1.00	0.50	0.25	0.10	0.05
liquid in the	2.0	2.0	2.0	1.8	1.3
loop (ml/cm)					

10 TABLE 2: TOXICITY CURVE OF MUTANT CT-S106

μ g of toxin	750	100	10	1	0.5
liquid in the	1.6	0.1	0.0	0.0	0.0
loop (ml/cm)					

15

2.2 Immunogenicity and Adjuvanticity.

The mucosal immunogenicity of CT-S106 and its adjuvanticity was tested using the protocol of Douce et al. (PNAS 92, 1644-1648 (1995)). Five mice were immunised intranasally with 1 μ g CT or CT-S106 and 10 μ g Fragment C of tetanus toxin. All the animals were immunized on day 1 and day 22. Responses were followed by assaying sample bleeds collected on day 0 and day 21. On day 35 the mice were challenged with 100xLD₅₀ tetanus toxin (The tetanus toxin was not completely active, so 100xLD₅₀ was used instead of 10xLD₅₀). The results are shown Tables 3 and 4.

TABLE 3

30 Titres of anti-CT specific IgG in sera of immunised mice

Mean antibody titre to cholera toxin after		
Immunogen	21 days	35 days
35 Wild-type CT	1:5800	1:87000
CT-S106	1:1250	1:11000

TABLE 4

	Immunogen	Animals with measurable antibody titres to tetanus toxin	Mean Antibody titre to tetanus toxin	Survival at 100xLD ₅₀ with tetanus toxin
5	(Intranasal Immunisation)			
10	Fragment C +CT	5/5	1:129399	5/5
15	Fragment C +CT-S106	5/5	1:23413	5/5
	Fragment C	2/5	1:393	2/5

20 These data show that intranasal immunisation with Fragment C of tetanus toxin alone does not afford protection against subsequent challenge. The additional presence of CT-S106, however, protects against lethal challenge with tetanus toxin, showing that CT-S106 acts as mucosal adjuvant.

25

CT-specific antibodies were measured using a GM1 capture ELISA (Douce et al.). Plates were coated overnight at 4°C with 100µl/well of 1.5µg/ml GM1 ganglioside solution (Sigma Chemical Co., St. Louis, USA). Plates were washed three times with PBS/T (PBS + 0.05% Tween 20). 200µl/well of 1% BSA were added and the plates were incubated for 1 hour at 37°C. 100µl/well of CT were added and incubated overnight at 4°C. Dilutions of serum from each mouse (1:50 dilution and eight subsequent 1:5 dilutions) were added to the wells. The plates were then incubated for 2 hours at 37°C, washed as described above, and incubated with anti-mouse immunoglobulin G conjugated to alkaline phosphatase (Sigma). After three washes, the substrate of alkaline phosphatase (pNPP) was added and the absorbancies were read at 405nm.

40 ELISA titres were determined arbitrarily as the dilution

corresponding to $OD_{405} = 0.3$.

Fragment C specific antibodies were measured using an ELISA. Plates were coated overnight at 4°C with 50µl/well of 10µg/ml tetanus toxoid diluted in PBS. Plates were washed three times with PBS/T. 200µl/well of 1% BSA were added and the plates were incubated for 1 hour at 37°C. Dilutions of serum from each mouse (1:50 dilution and eight subsequent 1:5 dilutions) were added to the wells. The plates were incubated for 2 hours at 37°C, washed as described above, and incubated with anti-mouse immunoglobulin G conjugated to alkaline phosphatase (Sigma). After three washes, the substrate of alkaline phosphatase (pNPP) was added and the absorbancies were read at 405nm. ELISA titres were determined arbitrarily as the dilution corresponding to $OD_{405} = 0.3$.

It will be understood that the invention is described above by way of example only and modifications may be made within the scope and spirit of the invention.

CLAIMS

1. An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a
5 fragment thereof, wherein at least one amino acid is substituted with another amino acid, characterised in that, in purified form, the immunogenic detoxified protein exhibits a residual toxicity greater than 10000 fold lower than its naturally occurring counterpart.
- 10 2. An immunogenic detoxified protein according to claim 1 wherein the amino acid at, or in a position corresponding to Pro-106 is replaced with another amino acid.
- 15 3. A vaccine composition comprising an immunogenic detoxified protein according to claim 1 or 2 and a pharmaceutically acceptable carrier.
4. A vaccine composition according to claim 3 further
20 comprising an adjuvant.
5. A vaccine composition according to claim 3 further containing a second immunogenic antigen.
- 25 6. A DNA sequence encoding an immunogenic detoxified protein according to claim 1 or 2.
7. A vector carrying a DNA according to claim 6.
- 30 8. A host cell line transformed with a vector according to claim 7.
9. A process for the production of an immunogenic detoxified protein according to claim 1 or 2 comprising
35 culturing a host cell according to claim 8.
10. A process for the production of a DNA according to

claim 6 comprising the steps of subjecting a DNA encoding a CT-A or a fragment thereof to site-directed mutagenesis.

11. A method of vaccinating a mammal against *Vibrio*
5 *cholerae* comprising administering an immunologically effective amount of an immunogenic detoxified protein according to claim 1 or 2.

12. A method for the prevention or treatment of disease
10 in a subject comprising administering to the subject an immunologically effective dose of a composition according to any one of claims 3 to 5.

13. A process for the formulation of a vaccine
15 composition according to claim 3 to 5 comprising bringing an immunogenic detoxified protein according to claim 1 into association with a pharmaceutically acceptable carrier.

14. A process for the formulation of a vaccine
20 according to claim 4 comprising bringing an immunogenic detoxified protein according to claim 1 into association with an adjuvant.

15. A process for the formulation of a vaccine
25 according to claim 5 comprising bringing an immunogenic detoxified protein according to claim 1 into association with a second antigen.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 97/00183

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K39/106 C07K14/28 C12N15/31		
According to International Patent Classification (IPC) or to both national classification and IPC:		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 02348 A (BIOCINE S.P.A. ;PIZZA MARIAGRAZIA (IT) ET AL.) 23 January 1997 cited in the application see the whole document ---	1,3-15
X	WO 93 13202 A (BIOCINE SCLAVO SPA) 8 July 1993 cited in the application see the whole document	1-4,6-14
Y	see especially claims 1-14 ---	5,15
X	WO 92 19265 A (AMGEN INC. ;UNIVERSITY OF SOUTHERN CALIFORNIA) 12 November 1992 cited in the application see the whole document ---	1,3,4,6-14
Y	---	5,15
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 25 June 1997		Date of mailing of the international search report 24. 07. 97
Name and mailing address of the ISA European Patent Office, P.O. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer Olsen, L

INTERNATIONAL SEARCH REPORT

Inter. nal Application No

PCT/IB 97/00183

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	INFECTION AND IMMUNITY, vol. 63, no. 6, June 1995, pages 2356-2360, XP002019078 FONTANA M. R. ET AL: "CONSTRUCTION OF NONTOXIC DERIVATIVES OF CHOLERA TOXIN AND CHARACTERIZATION OF THE IMMUNOLOGICAL RESPONSE AGAINST THE A SUBUNIT"	1,2,6-10
Y	see the whole document	3-5, 11-15
X	--- INFECTION AND IMMUNITY, vol. 59, no. 9, September 1991, pages 2870-2879, XP000654441 LOBET Y. ET AL: "EFFECT OF SITE-DIRECTED MUTAGENIC ALTERATIONS ON ADP-RIBOSYLTRANSFERASE ACTIVITY OF THE A SUBUNIT OF ESCHERIA COLI HEAT-LABILE ENTEROTOXIN"	1,6-10
Y	cited in the application see the whole document	3-5, 11-15
X	--- INFECTION AND IMMUNITY, vol. 59, no. 11, November 1991, pages 4266-4270, XP000654589 BURNETTE W.N. ET AL: "SITE-SPECIFIC MUTAGENESIS OF THE CATALYTIC SUBUNIT OF CHOLERA TOXIN: SUBSTITUTING LYSINE FOR ARGININE 7 CAUSES LOSS OF ACTIVITY"	1,6-10
Y	cited in the application see the whole document	3-5, 11-15
X	--- ABSTRACT B291 OF THE 92ND GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, 26-30TH MAY 1992, 1992, page 74 XP000654466 KASLOW H.R. ET AL: "EFFECTS OF SITE-DIRECTED MUTAGENESIS ON CHOLERA TOXIN A1 SUBUNIT ADP-RIBOSYLTRANSFERASE ACTIVITY"	1,6-10
Y	cited in the application	3-5, 11-15
Y	--- WO 95 17211 A (BIOCINE S.P.A. ;RAPPUOLI RINO (IT)) 29 June 1995 cited in the application see the whole document	5,15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 97/00183

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9702348 A	23-01-97	AU 6238896 A	05-02-97

WO 9313202 A	08-07-93	IT 1253009 B	10-07-95
		AU 3347693 A	28-07-93
		CA 2127091 A	08-07-93
		EP 0620850 A	26-10-94
		JP 7506240 T	13-07-95

WO 9219265 A	12-11-92	AU 665013 B	14-12-95
		AU 2293092 A	21-12-92
		CA 2102105 A	03-11-92
		CN 1067679 A	06-01-93
		EP 0584284 A	02-03-94
		JP 6507551 T	01-09-94

WO 9517211 A	29-06-95	AU 1278595 A	10-07-95
		CA 2179771 A	29-06-95
		EP 0732937 A	25-09-96
